摘要
目的观察奥沙利铂、氟尿嘧啶联合表柔比星经肝动脉化疗栓塞术(TACE)治疗原发性肝癌合并HIV/AIDS的疗效。方法采用随机数字表法将该院2013-06~2018-12收治的100例原发性肝癌合并HIV/AIDS患者分为观察组和对照组,每组50例。观察组采用奥沙利铂、氟尿嘧啶联合表柔比星经TACE治疗。对照组采用奥沙利铂和氟尿嘧啶经TACE治疗。比较两组临床疗效及不良反应情况。结果观察组临床疗效优于对照组,差异有统计学意义(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论奥沙利铂、氟尿嘧啶联合表柔比星经TACE治疗原发性肝癌合并HIV/AIDS具有良好的疗效及较高的安全性,值得临床推广。
Objective To observe the efficacy of oxaliplatin and fluorouracil combined with epirubicin in treatment of primary liver cancer complicated with HIV/AIDS via transcatheter arterial chemoembolization(TACE).Methods One hundred patients with primary liver cancer complicated with HIV/AIDS treated in our hospital from June 2013 to December 2018 were divided into observation group and control group by random number table method,with 50 cases in each group.The observation group was treated with oxaliplatin and fluorouracil combined with epirubicin via TACE.The control group was treated with oxaliplatin and fluorouracil through TACE.The clinical efficacy and adverse reactions were compared between the two groups.Results The clinical efficacy of the observation group was better than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Oxaliplatin and fluorouracil combined with epirubicin is effective and safe in treatment of primary liver cancer complicated with HIV/AIDS via TACE.The combination therapy is worthy of clinical application.
作者
蓝智
梁茂裕
莫伟杰
LAN Zhi;LIANG Mao-yu;MO Wei-jie(Department of General Surgery,the Fourth People′s Hospital of Nanning City,Guangxi Center for HIV/AIDS Clinical Treatment,Guangxi 530023,China)
出处
《中国临床新医学》
2019年第10期1094-1097,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
广西卫健委科研课题(编号:Z2012627)
关键词
奥沙利铂
氟尿嘧啶
表柔比星
肝动脉化疗栓塞术
原发性肝癌
人类免疫缺陷病毒
艾滋病
Oxaliplatin
Fluorouracil
Epirubicin
Transcatheter arterial chemoembolization(TACE)
Primary liver cancer
Human immunodeficiency virus(HIV)
Acquired immune deficiency syndrome(AIDS)
